Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

Federico Pirro, Ketty Peris, Clara De Simone, Giacomo Caldarola, Alessandro Di Stefani, M. Talamonti, M. Galluzzo, S. D’Adamio, M. Magnano, N. Bernardini, P. Malagoli, F. Bardazzi, C. Potenza, L. Bianchi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)

Abstract

Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants. Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3–4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.
Lingua originaleEnglish
pagine (da-a)665-672
Numero di pagine8
RivistaExpert Opinion on Biological Therapy
Volume20
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized
  • Drug Eruptions
  • Female
  • Humans
  • IL17
  • Interleukin-17
  • Male
  • Middle Aged
  • Psoriasis
  • Retrospective Studies
  • Skin
  • Steroids
  • Young Adult
  • anti IL17
  • eczematous reactions
  • ixekizumab
  • secukinumab
  • side effects

Fingerprint Entra nei temi di ricerca di 'Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature'. Insieme formano una fingerprint unica.

Cita questo